EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

The Gut Microbiome as a Biomarker and Therapeutic Target in Hepatocellular Carcinoma

Betul Gok Yavuz, Saumil Datar, Shadi Chamseddine iD, Yehia I Mohamed, Michael LaPelusa iD, Sunyoung S Lee, Zishuo Ian Hu, Eugene J Koay iD, Hop S Tran Cao iD, Prasun Kumar Jalal iD, Carrie Daniel-MacDougall iD, Manal Hassan und 3 weitere

Cancers · 07.10.2023 · 15 (19) · 4875

DOI: 10.3390/cancers15194875 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 07.10.2023. Verfasst von Betul Gok Yavuz und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Missouri, St. Louis, MO 63121, USA. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, University of Texas MD Anderson Cancer Center, SPORE in HCC.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The microbiome is pivotal in maintaining health and influencing disease by modulating essential inflammatory and immune responses. Hepatocellular carcinoma (HCC), ranking as the third most common cause of cancer-related fatalities globally, is influenced by the gut microbiome through bidirectional interactions between the gut and liver, as evidenced in both mouse models and human studies. Consequently, biomarkers based on gut microbiota represent promising non-invasive tools for the early detection of HCC. There is a growing body of evidence suggesting that the composition of the gut microbiota may play a role in the efficacy of immunotherapy in different types of cancer; thus, it could be used as a predictive biomarker. In this review, we will dissect the gut microbiome’s role as a potential predictive and diagnostic marker in HCC and evaluate the latest progress in leveraging the gut microbiome as a novel therapeutic avenue for HCC patients, with a special emphasis on immunotherapy.

Schlagwörter

Stichwörter der Autor:innen

biomarkersgut microbiomehepatocellular carcinomatherapeutic target

Autor:innen und Institutionen

  • Department of Medicine, University of Missouri, St. Louis, MO 63121, USA.
  • Department of Medicine, University of Texas at Houston, Houston, TX 77030, USA.
  • Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Hepato-Pancreato-Biliary Section, Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

ORCID-Profile: Shadi Chamseddine, Michael LaPelusa, Eugene J Koay, Hop S Tran Cao, Prasun Kumar Jalal, Carrie Daniel-MacDougall, Dan G Duda, Ahmed O Kaseb

Förderung

  • NCI NIH HHS
  • University of Texas MD Anderson Cancer Center, SPORE in HCC

Zitieren

APA

Gok Yavuz, B., Datar, S., Chamseddine, S., Mohamed, Y. I., LaPelusa, M., Lee, S. S., Hu, Z. I., Koay, E. J., Tran Cao, H. S., Jalal, P. K., Daniel-MacDougall, C., Hassan, M., Duda, D. G., Amin, H. M., & Kaseb, A. O. (2023). The Gut Microbiome as a Biomarker and Therapeutic Target in Hepatocellular Carcinoma. Cancers, 15(19), 4875. https://doi.org/10.3390/cancers15194875

Vancouver

Gok Yavuz B, Datar S, Chamseddine S, Mohamed YI, LaPelusa M, Lee SS, et al. The Gut Microbiome as a Biomarker and Therapeutic Target in Hepatocellular Carcinoma. Cancers. 2023;15(19):4875. doi:10.3390/cancers15194875

BibTeX
@article{GokYavuz2023,
  author = {Gok Yavuz, Betul and Datar, Saumil and Chamseddine, Shadi and Mohamed, Yehia I and LaPelusa, Michael and Lee, Sunyoung S and Hu, Zishuo Ian and Koay, Eugene J and Tran Cao, Hop S and Jalal, Prasun Kumar and Daniel-MacDougall, Carrie and Hassan, Manal and Duda, Dan G and Amin, Hesham M and Kaseb, Ahmed O},
  title = {The Gut Microbiome as a Biomarker and Therapeutic Target in Hepatocellular Carcinoma},
  journal = {Cancers},
  year = {2023},
  volume = {15},
  number = {19},
  pages = {4875},
  doi = {10.3390/cancers15194875}
}
Kostenlos starten →